Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Locally Advanced Mid-to-low Rectal Cancer: An Open-label, Multi-center, Randomized Controlled Trial

NCT07900061 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.

NCT NCT07900061 Not yet recruiting Phase 3 210 participants (estimated) Started 2026

Follow this trial by email Email me the PDF

Get the NCT07900061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started October 2026. Interventional study, Phase 3, 210 participants (estimated). Lead sponsor Sir Run Run Shaw Hospital. Primary measure: Disease Free Survival (DFS).

How it compares

213 similar trials: same condition (Rectal Neoplasms) and phase

Enrollment

This trial
210
Middle half
149 to 719
Median
336
Trials with a value
199

Months from start to completion

This trial
98.2
Middle half
53 to 118.1
Median
76.9
Trials with a value
167

Sites

This trial
Not reported
Middle half
1 to 34
Median
3
Trials with a value
196
Posted results or a linked paper 61% 129 of 213 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Locally Advanced Mid-to-low Rectal Cancer: An Open-label, Multi-center, Randomized Controlled Trial
Lead sponsor
Sir Run Run Shaw Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 25, 2026
Completion date
December 31, 2034
Enrollment
210 (estimated)
Sites
Not reported

Conditions

MeSH condition names; the registry's own terms follow.

Rectal Neoplasms

Registry terms: rectal cancer

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Lead sponsor
Sir Run Run Shaw Hospital

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
node-sparing modified short course radiotherapy combined with tislelizumab and CAPOX Experimental node-sparing modified short-course radiotherapy
Show registry wording

Radiotherapy: modified short-course radiotherapy for 5 days. CAPOX: Oxaliplatin 130 mg/m², once ivgtt on Day 1; Capecitabine 1000 mg/m², bid po from Day 1 to Day 14; q3w.

Tislelizumab: 200 mg, ivgtt on Day 1; q3w. Treatment cycles are repeated every 3 weeks for a total of 4 cycles.

standard short course radiotherapy combined with CAPOX Active comparator standard short-course radiotherapy
Show registry wording

standard short-course radiotherapy for 5 days. CAPOX: Oxaliplatin 130 mg/m², once ivgtt on Day 1; Capecitabine 1000 mg/m², bid po from Day 1 to Day 14; q3w.

Treatment cycles are repeated every 3 weeks for a total of 4 cycles.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Disease Free Survival (DFS) up to 5 years
Show registry wording

Time from randomization to the first occurrence of locoregional recurrence, distant metastasis, new invasive primary colorectal carcinoma or death from any cause, whichever occurs first.

Lead sponsor's other trials

Sir Run Run Shaw Hospital, most recent start first.

Similar trials

Same condition (Rectal Neoplasms) and phase, most recent start first.